OverviewSuggest Edit

Morphic Therapeutic operates as a biotechnology company. The company develops oral integrin drugs. It is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders, and immuno-oncology.
TypePublic
Founded2015
HQWaltham, US
Websitemorphictx.com

Latest Updates

Revenue (FY, 2019)$3.4 M
Share Price (Nov 2019)$15.1 (-2%)

Morphic Therapeutic Office Locations

Morphic Therapeutic has an office in Waltham
Waltham, US (HQ)
35 Gatehouse Dr
Show all (1)

Morphic Therapeutic Financials and Metrics

Morphic Therapeutic Revenue

Morphic Therapeutic's revenue was reported to be $3.36 m in FY, 2019
USD

Revenue (FY, 2019)

3.4m

Net income (FY, 2019)

(23.8m)

EBIT (FY, 2019)

(24.6m)

Market capitalization (8-Nov-2019)

459.6m

Closing stock price (8-Nov-2019)

15.1

Cash (31-Dec-2018)

185.9m
Morphic Therapeutic's current market capitalization is $459.6 m.
USDFY, 2017FY, 2019

Revenue

3.4m

General and administrative expense

2.8m5.4m

R&D expense

14.1m22.6m

Operating expense total

16.9m28.0m
USDFY, 2017FY, 2018

Cash

20.8m185.9m

Prepaid Expenses

479.0k1.2m

Current Assets

21.2m187.1m

PP&E

1.7m1.8m
USDFY, 2017FY, 2018

Net Income

(16.9m)(23.8m)

Depreciation and Amortization

434.0k539.0k

Accounts Payable

285.0k862.0k

Cash From Operating Activities

(15.4m)7.6m
Show all financial metrics

Morphic Therapeutic Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Morphic Security Corporation

Morphic Therapeutic Online and Social Media Presence

Embed Graph

Morphic Therapeutic Blogs

Morphic Therapeutic Appoints Former Gilead Leader Norbert Bischofberger, Ph.D., to Board of Directors

WALTHAM, Mass. – June 14, 2019 – Morphic Therapeutic, a biotechnology company developing oral integrin therapies, today announced the appointment of former Gilead chief scientific officer and executive vice president of research and development, Norbert Bischofberger, Ph.D., to its Board of Director…

Morphic Therapeutic Enters Into Integrin Research and Development Collaboration with Janssen

Deal extends reach of Morphic discovery across all known human integrins Therapeutic potential of Morphic pipeline expanded by inclusion of both integrin inhibitor and activator research Collaboration facilitated by Johnson & Johnson Innovation, Boston WALTHAM, Mass. – February 21, 2019 – Morphi…

Morphic Therapeutic to Present at 37th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. – January 2, 2019 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019.

AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases

Collaboration leverages Morphic’s unique platform for developing oral integrin drugs and AbbVie’s global development and commercialization capabilities NORTH CHICAGO, Ill. and WALTHAM, Mass. – October 18, 2018 – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Morphic The…

Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics through Clinical Proof of Concept

Series B financing led by Omega Funds and Novo Holdings Financing to enable the initiation of IND-enabling and clinical studies in 2019 WALTHAM, Mass. – September 25, 2018 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that it…

High integrin affinity reached by hybrid domain deletion

Check out Morphic's recent joint publication with Springer lab and see how the binding affinity and kinetics of pro-TGFβ to integrin αvβ6 are regulated by the receptor conformation. https://timothyspringer.org/publications/high-integrin-alphavbeta6-affinity-reached-hybrid-domain-deletion-slows-ligand-binding

Morphic Therapeutic Frequently Asked Questions

  • When was Morphic Therapeutic founded?

    Morphic Therapeutic was founded in 2015.

  • What is Morphic Therapeutic revenue?

    Latest Morphic Therapeutic annual revenue is $3.4 m.

  • Who are Morphic Therapeutic competitors?

    Competitors of Morphic Therapeutic include KinDex Pharmaceuticals, Valneva and Therapeutic Solutions International.

  • Where is Morphic Therapeutic headquarters?

    Morphic Therapeutic headquarters is located at 35 Gatehouse Dr, Waltham.

  • Where are Morphic Therapeutic offices?

    Morphic Therapeutic has an office in Waltham.

  • How many offices does Morphic Therapeutic have?

    Morphic Therapeutic has 1 office.